Goldman Sachs Group Inc. Increases BioMarin Pharmaceutical Price Target to $85.00 (BMRN)
Goldman Sachs Group Inc. upped their price target on shares of BioMarin Pharmaceutical (NYSE:BMRN) from $76.00 to $85.00 in a research note issued on Wednesday, American Banking & Market News reports. Goldman Sachs Group Inc.’s target price would suggest a potential upside of 9.69% from the company’s current price.
Separately, analysts at Cowen and Company raised their price target on shares of BioMarin Pharmaceutical (NYSE:BMRN) from $79.00 to $85.00 in a research note to investors on Wednesday. They now have an “outperform” rating on the stock.
One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $84.20.
Shares of BioMarin Pharmaceutical (NYSE:BMRN) traded up 2.02% on Wednesday, hitting $77.492. The stock had a trading volume of 3,191,145 shares. BioMarin Pharmaceutical has a 1-year low of $36.28 and a 1-year high of $78.83. The stock has a 50-day moving average of $67.2 and a 200-day moving average of $63.36. The company’s market cap is $10.857 billion.
BioMarin Pharmaceutical Inc (NYSE:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.